SQUAWK/NEWS
Menu
Live News EQUITY L impact

NMRA - Neumora Therapeutics Reports Favorable NMRA-215 Toxicology Results with Planned Clinical Advancement in 2026 - Click For Release

NMRA - Neumora Therapeutics Reports Favorable NMRA-215 Toxicology Results with Planned Clinical Advancement in 2026 - Click For Release

Story updates

11:02:12 AM UTC
SquawkNews
NMRA Neumora Therapeutics reports favorable nmra-215 toxicology results with planned clinical advancement in 2026 Neumora Therapeutics - repeat 13-week rat toxicology study shows no unexpected in-life adverse findings - Plans to submit ind application for nmra-215 in Q4 2026 - Anticipates initiating clinical study for nmra-215 in 2026
11:08:47 AM UTC
SquawkNews
Neumora Therapeutics reports pre-clinical toxicology results from NMRA-215 study

NMRA Neumora Therapeutics reports favorable nmra-215 toxicology results with planned clinical advancement in 2026 Neumora Therapeutics - repeat 13-week rat toxicology study shows no unexpected in-life adverse findings - Plans to submit ind application for nmra-215 in Q4 2026 - Anticipates initiating clinical study for nmra-215 in 2026